iBio, Inc. IBIO
Set alert
At close · Nov 2
After hours · Nov 2, 6:46 PM ET
- YTD
- -58.55%
- 1 year
- -50.01%
- Open
- 0.80
- Prev close
- 0.7687
- Mkt cap
- 39.74M
- Vol
- 307.11K
- Avg vol
- 707.20K
- EPS
- -0.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.75
- High
- 0.80
- Forward P/E
- -1.44
- Beta
- 0.00
- Short ratio
- 1.92
- Inst. own
- 31.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2025
- 50-d avg
- 2.60
- 200-d avg
- 2.17
- 1y target
- 3.60
5Y chart
Events in this range
- Oct 10, 2022Split: 1 for 25
- Nov 14, 2023Earnings: -4.2; estimate 0; surprise —%
- Nov 29, 2023Split: 1 for 20
- Feb 9, 2024Earnings: -2.42; estimate 0; surprise —%
- May 13, 2024Earnings: -0.71; estimate 0; surprise —%
- May 28, 2024Rating: Chardan Capital · — → Buy
- Jun 3, 2024Rating: Chardan Capital · Buy → Buy
- Jul 22, 2024Rating: Brookline Capital · — → Buy
- Sep 25, 2024Earnings: —; estimate -0.46; surprise —%
- Nov 12, 2024Earnings: -0.46; estimate -0.46; surprise 0%
- Dec 17, 2024Rating: LUCID CAPITAL MARKETS · — → Buy
- Feb 14, 2025Earnings: —; estimate -0.45; surprise —%
Signals (60)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| RSI: Overbought | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| RSI: Overbought | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
Newest 20 of 60.
Key statistics
- Market cap
- 21.59M
- Enterprise value
- 16.08M
- Trailing P/E
- 0.00
- Forward P/E
- -1.44
- PEG ratio
- 0.00
- Price / sales
- 123.39
- Price / book
- 1.15
- EPS (TTM)
- -0.25
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 175.00K
- Revenue growth
- 0.00%
- Free cash flow
- 10.15M
- Total cash
- 11.04M
- Total debt
- 4.43M
- Return on equity
- -92.74%
- Shares outstanding
- 9.15M
- Short % of float
- 2.22%
- 50-day average
- 2.60
- 200-day average
- 2.17
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 14, 2025
Expected Feb 14, 2025. Consensus EPS estimate -0.45.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 14, 2025 | Dec 1, 2024 | -0.45 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | -0.46 | -0.46 | 0.00 | 0.00% |
| Sep 25, 2024 | Jun 1, 2024 | -0.46 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.71 | — | — |
| Feb 9, 2024 | Dec 1, 2023 | 0.00 | -2.42 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -4.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | LUCID CAPITAL MARKETS | init | — | Buy |
| Jul 22, 2024 | Brookline Capital | init | — | Buy |
| Jun 3, 2024 | Chardan Capital | main | Buy | Buy |
| May 28, 2024 | Chardan Capital | init | — | Buy |
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ibioinc.com
News
- iBio to Participate in Upcoming Investor Conferences
- Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
- iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy
- Squarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIO
- This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
- 12 Health Care Stocks Moving In Monday's After-Market Session
- iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Your note
Sign in to keep a note on IBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNER MARTIN | Chief Executive Officer | Sale | Oct 31, 2023 | 182,502 |
| DURAN FELIPE | Chief Financial Officer | Stock Award(Grant) | Mar 30, 2023 | 39,633 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 9.42% | 862,279 | 2.03M | Sep 29, 2024 |
| Ikarian Capital, LLC | 6.56% | 600,000 | 1.42M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 5.20% | 476,212 | 1.12M | Sep 29, 2024 |
| Opaleye Management Inc. | 4.10% | 375,000 | 885.00K | Sep 29, 2024 |
| Boothbay Fund Management, LLC | 1.74% | 159,535 | 376.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.60% | 55,022 | 129.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.52% | 47,472 | 112.03K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 35,998 | 84.95K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 15,822 | 37.34K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 12,841 | 30.30K | Oct 30, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.09% | 8,284 | 19.55K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.05% | 4,653 | 10.98K | Jul 30, 2024 |